Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (206)	11/22/1999 6:13:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 557

I see that TGEN went out of its way to distance its AAV products from the Adenovirus vectors. biz.yahoo.com Bravo! Mike, you've persuaded me that the run-up in Avigen's stock is getting a bit frothy. TGEN looks like a much better investment: its price is dirt cheap (not much downside risk), and to the extent Avigen establishes the viability of AAV as a gene therapy vector, TGEN should enjoy enjoy some of the upside from that good news. I sold some Avigen today and bought TGEN with the proceeds. I'm still bullish Avigen and kept the lion's share of my holdings, but I like the idea of diversification. Marc

To: Mike McFarland who wrote (206)	1/28/2000 9:14:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

AMENDMENTS AND UPDATES... December 8-10, 1999 www4.od.nih.gov October 15, 1999 9409-083 Zeitlin A Phase I Study of an Adeno-Associated Virus-CFTR Gene Vector in Adult CF Patients with Mild Lung Disease Amendments: 1) One new site/investigator is added. Terence R. Flotte, M.D.; University of Florida; Gainesville, Florida. 2) Large number of amendments have been made. Significant changes are that, based upon rabbit toxicological data, the maximum dose will now be 1x10^9 RU (replication units) of tgAAVCF administered to the lung. In addition, the lower age has been changed from 18 to 15 years old.